|
Combination treatment for psoriasis |
Agents | Outcomes |
|
Topical vitamin D analogues and corticosteroids | Patients had a 22% (95% CI: 12%–33%) increased likelihood of clearance than did patients receiving vitamin D derivative monotherapy |
Topical vitamin D analogues and UV-B phototherapy | Patients had no statistically significant increase (11%; 95% CI: 2%–24%) in the likelihood of clearance than did patients receiving UV-B monotherapy |
Topical retinoids and vitamin D analogues | Patients had a 33% (95% CI: 22%–44%) increased likelihood clearance than did patients receiving topical retinoids monotherapy |
Topical corticosteroids and salicylic acid | Patients had no statistically significant increase (3%; 95% CI: 0%–7%) in the likelihood of clearance than did patients receiving UV-B monotherapy |
Topical corticosteroids and UV-B phototherapy | Patients had no statistically significant increase (−6%; 95% CI: −24%–12%) in the likelihood of clearance than did patients receiving UV-B monotherapy |
Topical retinoids and corticosteroids | Patients had a 19% (95% CI: 11%–27%) increased likelihood of clearance than did patients receiving vitamin A derivative monotherapy |
Topical retinoids and UV-B phototherapy | Patients had a 21% (95% CI: 5%–36%) increased likelihood of clearance than did patients receiving UV-B monotherapy |
UV-B phototherapy and biological agents | Patients had a 68% (95% CI: 51%–85%) increased likelihood of clearance than did patients receiving alefacept monotherapy |
UV-B phototherapy and methotrexate | Patients had a 36% (95% CI: 10%–63%) increased likelihood clearance than did patients receiving UV-B-methotrexate monotherapy |
|